Boye L Jensen Selected Research

Polydipsia

11/2020	A mini-review of pharmacological strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus.
5/2009	Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Boye L Jensen Research Topics

Disease

32	Hypertension (High Blood Pressure) 04/2024 - 01/2008
19	Proteinuria 02/2024 - 09/2011
13	Albuminuria 03/2024 - 02/2012
13	Nephrotic Syndrome (Syndrome, Nephrotic) 03/2020 - 02/2009
12	Pre-Eclampsia (Preeclampsia) 01/2024 - 01/2012
11	Fibrosis (Cirrhosis) 02/2024 - 02/2013
8	Diabetic Nephropathies (Diabetic Nephropathy) 03/2024 - 01/2012
7	Ureteral Obstruction 01/2022 - 08/2005
6	Type 2 Diabetes Mellitus (MODY) 03/2024 - 08/2014
6	Inflammation (Inflammations) 01/2023 - 01/2016
6	Polyuria 11/2020 - 05/2007
5	Hypoxia (Hypoxemia) 01/2021 - 05/2004
4	Nephrogenic Diabetes Insipidus 10/2022 - 01/2014
4	Body Weight (Weight, Body) 01/2022 - 09/2008
4	Hydronephrosis 01/2022 - 07/2013
4	Ascites 01/2020 - 05/2005
4	Weight Loss (Weight Reduction) 12/2019 - 09/2007
3	Edema (Dropsy) 03/2020 - 08/2015
3	Nephrosis 12/2019 - 03/2015
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2016 - 07/2006
3	Neoplasms (Cancer) 01/2016 - 05/2004
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 07/2016
2	Hyponatremia 11/2023 - 10/2023
2	Hemorrhage 11/2023 - 05/2004
2	Appendicitis 10/2023 - 01/2019
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2023 - 01/2020
2	Vascular Diseases (Vascular Disease) 01/2023 - 01/2021
2	Hypertrophy 01/2022 - 11/2015
2	Chronic Renal Insufficiency 10/2021 - 01/2021
2	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 01/2018
2	Polydipsia 11/2020 - 05/2009
2	Hyperkalemia 01/2018 - 12/2014
2	Endotoxemia 10/2013 - 08/2011
2	Weight Gain 09/2008 - 09/2007
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2007 - 05/2005
2	Pathologic Constriction (Stenosis) 05/2004 - 05/2004

Drug/Important Bio-Agent (IBA)

21	Fibrinolysin FDA Link 01/2024 - 02/2009
21	SodiumIBA 11/2023 - 05/2005
13	AldosteroneIBA 01/2024 - 05/2009
13	PlasminogenIBA 01/2024 - 02/2009
13	SaltsIBA 01/2024 - 01/2008
13	Proteins (Proteins, Gene)FDA Link 01/2024 - 07/2006
10	Amiloride (Midamor)FDA LinkGeneric 01/2024 - 12/2014
9	Angiotensin IIIBA 04/2024 - 05/2004
8	ReninIBA 12/2020 - 05/2009
8	Epithelial Sodium ChannelsIBA 12/2020 - 02/2009
7	Spironolactone (Aldactone)FDA LinkGeneric 02/2024 - 08/2006
7	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2024 - 02/2009
6	AlbuminsIBA 01/2023 - 08/2014
6	prostasinIBA 12/2019 - 01/2015
6	Peptide Hydrolases (Proteases)FDA Link 12/2019 - 09/2011
5	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2024 - 01/2007
5	CreatinineIBA 01/2023 - 12/2014
5	LithiumIBA 03/2016 - 09/2008
4	Complement System Proteins (Complement)IBA 03/2024 - 01/2022
4	Vasopressins (Vasopressin)IBA 11/2023 - 01/2014
4	estropipate (Ogen)FDA LinkGeneric 01/2023 - 11/2012
4	Aquaporin 2IBA 10/2022 - 04/2010
4	Messenger RNA (mRNA)IBA 01/2022 - 05/2004
4	Serine Proteases (Serine Protease)IBA 01/2018 - 01/2012
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 03/2024 - 01/2022
3	complement C3d,gIBA 01/2024 - 01/2022
3	CytokinesIBA 01/2024 - 01/2021
3	AngiotensinsIBA 01/2022 - 05/2009
3	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 02/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 03/2010
3	Atrial Natriuretic Factor (ANF)IBA 01/2021 - 03/2015
3	DiureticsIBA 01/2021 - 08/2014
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 01/2008
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2020 - 04/2010
3	FurinIBA 12/2019 - 01/2015
3	Puromycin AminonucleosideIBA 12/2019 - 01/2012
3	Arginine (L-Arginine)FDA Link 01/2019 - 10/2013
3	PotassiumIBA 01/2019 - 02/2013
3	Superoxides (Superoxide)IBA 10/2016 - 10/2013
3	EnzymesIBA 12/2015 - 01/2007
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2014 - 08/2011
3	Aquaporins (Water Channels)IBA 06/2012 - 08/2005
3	Oxygen (Dioxygen)IBA 01/2009 - 05/2004
3	AdrenomedullinIBA 01/2009 - 05/2004
2	NPHS2 proteinIBA 01/2024 - 12/2019
2	Interleukin-17 (Interleukin 17)IBA 01/2024 - 01/2022
2	Interleukin-6 (Interleukin 6)IBA 01/2024 - 01/2022
2	Arginine Vasopressin (Argipressin)IBA 11/2023 - 11/2020
2	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2019
2	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2022
2	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2020 - 04/2016
2	GlucocorticoidsIBA 01/2020 - 01/2007
2	Dietary SodiumIBA 01/2019 - 01/2008
2	NitratesIBA 01/2019 - 10/2016
2	Kallikreins (Kallikrein)IBA 03/2015 - 01/2015
2	parecoxibIBA 01/2014 - 09/2007
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2014 - 09/2007
2	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 10/2013 - 08/2011
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2013 - 02/2013

Therapy/Procedure

3	Therapeutics 02/2024 - 09/2008
2	Nephrectomy 01/2022 - 01/2017
2	Renal Dialysis (Hemodialysis) 10/2021 - 08/2011